How aging at the cellular level affects blood cancer outcomes

Plain-English translation of NCT06022328 on ClinicalTrials.gov ↗ · Source last updated July 2025 · Translation generated June 2026 · How we translate trials

What is this trial?

This research study is investigating a new way to understand myeloproliferative neoplasms — blood cancers that cause your bone marrow to make too many blood cells. Instead of just looking at your age and standard genetic mutations, researchers want to study your DNA's epigenetic age (a measure of how "old" your cells appear at a molecular level) to see if it can help predict who will develop serious complications like blood clots or disease progression.

Doctors currently predict outcomes in these blood cancers mainly based on age and certain genetic mutations, but this doesn't tell the whole story. Recent research suggests that cellular aging — measured through DNA changes — may help doctors better understand who is at highest risk for dangerous blood clots or disease transformation into more serious forms of cancer.

Do you qualify?

You likely qualify if…

you have been diagnosed with essential thrombocythemia, polycythemia vera, or primary myelofibrosis
you had blood cells collected and stored at the time of your diagnosis
you have not been treated with certain chemotherapy or immunosuppressive drugs at the time of sample collection
you have been followed by your doctors for at least 2 years since your diagnosis

You likely don't qualify if…

you are currently taking or were taking cytoreductive drugs, chemotherapy, or immunosuppressive therapy at the time your blood sample was collected
you do not have a stored blood sample from the time of your original diagnosis
you have been diagnosed with a different type of blood cancer or solid tumor
you have less than 2 years of follow-up medical records available

What participation looks like

Participation is straightforward — researchers will use blood samples that were already collected and stored from the time you were first diagnosed. They will analyze your DNA to measure your epigenetic age and compare it to other patients with your condition who had different outcomes (some had blood clots, some progressed to more serious disease, and some remained stable). You will not need to undergo any new procedures or take any new medications for this study.

AI-generated summary from trial data · Jun 27, 2026 · Not medical advice

Trial locations(1 site)

France

CHU de Bordeaux, service Hématologie Biologique, Bordeaux